Back to catalogue
SYNC
Syncona Limited
400/1000 Overall fit
AI beneficiary 35% 28
Operating leverage 25% 35
Valuation 25% 55
Downside protection 15% 50
First-pass take
Syncona is a listed investment company with zero AI exposure and no operating leverage—it passively deploys capital in biotech. The 48% NAV discount and £369m cash provide discipline, but the portfolio suffered 17% losses in sector downturn with significant clinical/regulatory risk. Not a fit for AI/operating-leverage strategy.
Flags
investment-companybiotech-focusedsector-downturnliac-discountclinical-execution-riskcapital-markets-dependent